Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"Unlimited Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unlimited Sciences Announces Groundbreaking New Study to Observe Ayahuasca\u2019s Effects on Trauma","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Unlimited Sciences

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Ayahuasca produces powerful experiences that have been likened to intense psychotherapy, indicating its therapeutic potential for treating trauma and its resulting mental health disorders, such as post-traumatic stress disorder (PTSD).

            Lead Product(s): Dimethyltryptamine

            Therapeutic Area: Psychiatry/Psychology Product Name: Ayahuasca

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 02, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY